Newron Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	283	476	174	88	28	29
Market Cap Growth	94.24%	173.36%	97.16%	219.36%	-4.32%	-24.65%
Enterprise Value	292	485	209	118	44	34
Last Close Price	14.14	23.85	8.95	4.95	1.55	1.62
PE Ratio	-	-	11.72	-	-	-
Forward PE	-	-	10.63	-	7.84	-
PS Ratio	15.89	26.74	3.61	10.48	4.59	4.84
PB Ratio	-27.30	-45.92	127.32	-3.17	-1.99	8.98
P/TBV Ratio	-	-	127.32	-	-	8.98
P/FCF Ratio	9.41	15.83	-	-	-	-
P/OCF Ratio	9.40	15.81	-	-	-	-
EV/Sales Ratio	16.38	27.23	4.34	13.95	7.26	5.77
EV/EBITDA Ratio	-	-	8.52	-	-	-
EV/EBIT Ratio	-	-	8.53	-	-	-
EV/FCF Ratio	9.70	16.12	-	-	-	-
Debt / Equity Ratio	-3.43	-3.43	34.62	-1.62	-3.25	13.87
Debt / EBITDA Ratio	-	-	1.91	-	-	-
Debt / FCF Ratio	1.18	1.18	-	-	-	-
Net Debt / Equity Ratio	-0.83	-0.83	27.88	-1.20	-1.63	2.73
Net Debt / EBITDA Ratio	-1.99	-1.99	1.55	-3.12	-1.72	-0.69
Net Debt / FCF Ratio	0.29	0.29	-2.31	-3.53	-2.06	-0.74
Asset Turnover	0.37	0.37	1.15	0.29	0.14	0.11
Quick Ratio	0.70	0.70	2.42	0.62	5.50	10.58
Current Ratio	0.76	0.76	2.60	0.68	5.65	10.79
Return on Equity (ROE)	-	-	-	-	-	-146.43%
Return on Assets (ROA)	-5.65%	-5.65%	36.44%	-23.05%	-18.96%	-15.19%
Return on Invested Capital (ROIC)	-	-23.34%	80.74%	-157.51%	-130.08%	-103.26%
Return on Capital Employed (ROCE)	46.60%	46.60%	64.80%	380.00%	-41.40%	-26.40%
Earnings Yield	-4.36%	-2.59%	8.54%	-17.09%	-62.50%	-53.44%
FCF Yield	10.63%	6.32%	-9.50%	-10.70%	-39.69%	-41.12%
Buyback Yield / Dilution	2.98%	2.98%	-15.30%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.